National Cancer Institute
U.S. National Institutes of Health |

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
About NCI
The Prostate Cancer Prevention Trial
    Posted: 05/22/2003    Updated: 12/12/2007



NCI Materials

PCPT Publications


Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

Past Highlights
Related Pages:
The SELECT Prostate Cancer Prevention Trial
A collection of material about SELECT (Selenium and Vitamin E Cancer Prevention Trial), which will determine whether these two dietary supplements can protect against prostate cancer.

Prostate Cancer Home Page
NCI's gateway for information about prostate cancer.

Prostate Cancer (PDQ®): Prevention
Expert-reviewed information summary about factors that may influence the risk of developing prostate cancer and about research aimed at the prevention of this disease. (Health professional version.)

The Prostate Cancer Prevention Trial, or PCPT, is a study designed to see whether the drug finasteride (trade name Proscar) can prevent prostate cancer in men ages 55 and older. (See a summary of the protocol.)

Prostate Cancer Prevention TrialIn June 2003, the PCPT was stopped early because of a clear finding that finasteride reduced the incidence of prostate cancer. However, those trial participants who did develop prostate cancer while taking finasteride experienced a slightly higher incidence of high-grade tumors. Researchers analyzing the data have shown that because men taking finasteride have a reduced prostate size, this contributes to finding more high-grade tumors on biopsy. Additionally, researchers also found that high-grade cancer was detected earlier and in a less extensive stage in the finasteride group than in the placebo group.

Specimens from the PCPT biorepository are also available for research by other groups. Guidelines on how to get access to the PCPT biospecimens were released in late 2006.

The links on the left of this page will take you to more detailed information about the trial and its results so far.

Prostate cancer is a critical public health problem: more than 220,000 men will be diagnosed with prostate cancer in the United States this year and almost 29,000 will die of the disease.

Next Section >

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health